Home / Expertise / Life Sciences & Healthcare

Life Sciences & Healthcare

Netherlands

We work for top 100 enterprise. For example farmaceutical companies ranked in the global top 20. Furthermore, nine out of ten of the global producers of medical instruments are part of our client base. To our lawyers – who often have an in-house history in your industry themselves – your industry has no secrets. The marketing of medicinal products. Public procurement. Pricing and reimbursement. The protection of patents. Or agreements for clinical trials. We know what you are talking about. That is why we assist our top clients with their strategic decisions, the structuring of their business transactions and in legal proceedings.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology and medical devices. With active memberships in major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the lifesciences sector. We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice. Equally, when you need lifesciences specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

Read more Read less

‘Speedy responses and practical advice in pharma and corporate law matters.’

The Legal 500 EMEA, 2020

"really brilliant" , "broad network" and that the firm "co-ordinates things well".

Chambers Europe-wide, 2020

"Really efficient and quick."

Chambers Global, 2020

"The firm is a reliable international firm that has shown us a deep knowledge of the applicable law and significant practical experience on relevant cases."

Chambers Global, 2020

"Extremely responsive and overall always felt that I was in extremely safe hands."

Chambers Global, 2019

"They are very well connected with their team; they really use the benefit of working together in their various offices."

Chambers Global, 2019

A client describes the lawyers as "subject matter experts".

Chambers Europe, 2019

Clients praise the firm's international network as a key advantage, particularly appreciating that "it is able to provide expertise across multiple jurisdictions. This co-operation is done in a very expedient and uncomplicated manner."

Chambers Europe, 2019

"The CMS team offers a broad range of expertise including regulatory, IP, and competition."

The Legal 500, 2019

In M&A the firm has a good reputation for working in the hospitality, life sciences and oil and gas sectors.

IFLR1000, 2019

Choose area

    Pharmaceuticals

    Pharmaceutical and healthcare law focuses on all the special legislation and legal aspects to do with medicine provision, biotechnology and healthcare. Whether it concerns manufacturing, operations, licences, rates, quality, market regulation or care insurance, there is specific legislation for all these areas.

    Read more
    02/04/2019
    WLG Can­nabis Leg­al­iz­a­tion: Europe Up­date
    What is the status of can­nabis lib­er­al­iz­a­tion in the Neth­er­lands, Ger­many and Spain? Pan­el­ists El­len Gielen (CMS Neth­er­lands), Jörn Witt, Susanne Pech (both CMS Ger­many) and Juan Car­los Hernanz (Cuatreca­s­as, Spain) will give an up­date on their jur­is­dic­tion. Steven Stein (Green­berg Glusk­er) ac­ted as a mod­er­at­or.Length: 57:30 minutesSource: World Law GroupType: We­bin­ar re­cord­ingLan­guage: Eng­lishSize: 26,3 MBme­di­umme­di­umme­di­um
    Sub­scribe to Life Sci­ences & Health­care top­ics
    May 2020
    CMS Life Sci­ences & Health­care Glob­al Bro­chure
    With more than 300 law­yers, pat­ent at­tor­neys, sci­ent­ists and aca­dem­ics’ across CMS and the sup­port of the Life Sci­ences Asia-Pa­cific Net­work (LAN), we un­der­stand the sci­entif­ic and com­mer­cial as well as the leg­al im­per­at­ives af­fect­ing your life sci­ences & health­care busi­ness. We work with and have es­tab­lished long-term re­la­tion­ships with the top 100 life sci­ences & health­care com­pan­ies in the areas of phar­ma­ceut­ic­als, med­ic­al devices, bi­o­tech­no­logy, ag­ri­cul­ture and food, in­clud­ing the top 20 glob­al phar­ma­ceut­ic­al com­pan­ies and nine out of the top ten glob­al med­ic­al device com­pan­ies. Our ex­perts, many of whom have worked in-house in your sec­tor, have de­veloped a shared cap­ab­il­ity in the areas of phar­ma­ceut­ic­als, bi­o­tech­no­logy, med­ic­al devices and dia­gnostics. With act­ive mem­ber­ships in ma­jor in­dustry as­so­ci­ations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the leg­al frame­works im­pact­ing the life sci­ences & health­care sec­tor. We reg­u­larly ad­vise our cli­ents on their day-to-day op­er­a­tion­al needs such as sup­port with ad­vert­ise­ment and pro­mo­tion of medi­cine, pub­lic sec­tor pro­cure­ment, pri­cing and re­im­burse­ment, pat­ent en­force­ment, com­mer­cial and clin­ic­al tri­al agree­ments as well as reg­u­lat­ory ad­vice. Equally, when you need life sci­ences & health­care spe­cial­ist ad­vice for stra­tegic agree­ments, plan­ning a cor­por­ate trans­ac­tion or em­bark­ing on lit­ig­a­tion (wheth­er product li­ab­il­ity or oth­er­wise), we have a team that is well versed in the in­dustry is­sues to help you. 

    Feed

    Show only
    07 July 2020
    CMS ad­vises Im­mat­ics on the busi­ness com­bin­a­tion with Arya Sci­ences Ac­quis­i­tion...
    20 April 2020
    CMS Ex­pert Guide to ad­vert­ising of medi­cines and med­ic­al devices
    Are you look­ing for in­form­a­tion on phar­ma­ceut­ic­al ad­vert­ising reg­u­la­tion and med­ic­al device ad­vert­ising? Learn more about it in this CMS Ex­pert Guide.
    08 July 2020
    “WIPO PROOF”: WIPO’s new on­line ser­vice which helps in­nov­at­ors and cre­at­ors...
    The World In­tel­lec­tu­al Prop­erty Or­gan­isa­tion (WIPO) re­cently launched its new on­line busi­ness ser­vice, “WIPO PROOF”. The plat­form aims to help in­nov­at­ors and cre­at­ors safe­guard their in­tel­lec­tu­al...
    07 July 2020
    On the Pulse
    Wel­come to ‘On the Pulse’ de­livered by the Glob­al Life Sci­ences & Health­care Sec­tor Group
    20 April 2020
    CMS Ex­pert Guide to can­nabis law and le­gis­la­tion
    Are you look­ing for in­form­a­tion on can­nabis law and le­gis­la­tion? This CMS Ex­pert Guide provides you with everything you need to know.
    02 July 2020
    EU agrees new class ac­tion re­gime for con­sumer dis­putes
    After a long gest­a­tion, on 30 June 2020 the Coun­cil of the EU pub­lished the text for the col­lect­ive re­dress dir­ect­ive (the “CR Dir­ect­ive”) (text avail­able here). This le­gis­la­tion is in­ten­ded to bet­ter...
    17 June 2020
    Pod­cast: Ad­vert­ising of Medi­cines and Med­ic­al Devices
    Epis­ode #2 of On the Pulse brought to you by the Glob­al Life Sci­ences & Health­care Sec­tor Group
    26 May 2020
    European Com­mis­sion must ad­dress in­tel­lec­tu­al prop­erty and AI
    The Com­mit­tee on Leg­al Af­fairs (JURI) of the European Par­lia­ment has pub­lished three draft re­ports re­lat­ing to ar­ti­fi­cial in­tel­li­gence (AI). This note is about the draft re­port on in­tel­lec­tu­al prop­erty...
    04/05/2020
    5 mis­con­cep­tions about the GDPR data breach no­ti­fic­a­tion
    22 May 2020
    For­eign in­vest­ments in Ger­man life sci­ence com­pan­ies be­come sub­ject to...
    In re­sponse to the COV­ID-19 pan­dem­ic, Ger­many has widened the scope of its in­vest­ment con­trol to in­clude nu­mer­ous life sci­ence com­pan­ies. The amend­ments to the For­eign Trade and Pay­ments Or­din­ance ("AWV")...
    20/03/2020
    CMS as­sists Dutch com­pany with the sale and dis­tri­bu­tion of ap­proved corona...
    04 May 2020
    EPO Board of ap­peal re­mits to ex­amin­ing di­vi­sion when pri­or art search...
    In Mod­el de­term­in­a­tion sys­tem/Ac­cen­ture Glob­al Ser­vices Lim­ited (Case T-1159/15), the board of ap­peal finds that need to per­form a pri­or art search con­sti­tutes a spe­cial reas­on to re­mit the ap­peal ap­plic­a­tion...